SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-12.9%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$1.16B
AUM Growth
+$1.16B
(-9.3%)
Cap. Flow
+$54.5M
Cap. Flow
% of AUM
4.71%
Top 10 Holdings %
Top 10 Hldgs %
99.95%
Holding
11
New
1
Increased
3
Reduced
1
Closed
–
Top Buys
| 1 |
AMRN
Amarin Corp
AMRN
|
$36.2M |
| 2 |
Alkermes
ALKS
|
$19.2M |
| 3 |
PEAR
Pear Therapeutics, Inc. Class A Common Stock
PEAR
|
$3.1M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$1.56M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$5.66M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alkermes
ALKS
$4.78B
| $327M | 28.27% | 14,040,000 +827,000 | +6% | +$19.2M |
|
|
2
Gilead Sciences
GILD
$140B
| $210M | 18.16% | 2,889,300 -78,000 | -3% | -$5.66M |
|
3
Ironwood Pharmaceuticals
IRWD
$214M
| $191M | 16.54% | 16,390,000 | – | – |
|
4
Biogen
BIIB
$19.4B
| $154M | 13.35% | 643,000 | – | – |
|
5
Innoviva
INVA
$1.29B
| $114M | 9.88% | 6,614,000 | – | – |
|
|
AMRN
6
Amarin Corp
AMRN
$311M
| $64.9M | 5.62% | 19,250,000 +10,750,000 | +126% | +$36.2M |
|
|
7
BioCryst Pharmaceuticals
BCRX
$1.74B
| $55.9M | 4.84% | 4,039,600 +112,900 | +3% | +$1.56M |
|
8
Mersana Therapeutics
MRSN
$36.5M
| $26.7M | 2.31% | 4,299,297 | – | – |
|
9
Vor Biopharma
VOR
$250M
| $8.22M | 0.71% | 707,010 | – | – |
|
|
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $3.1M | 0.27% | +500,356 | New | +$3.1M |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $583K | 0.05% | 1,851,851 | – | – |
|